Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 15/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.45 |
| ▸ | MARK3 | P27448 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | NEK4 | P51957 | 1/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.45 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.45 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.45 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123442 | 0.91 | HDAC1 (0.46) | ITKAURKAMAP4K4CHEK2PRKCG | |
| SCHEMBL7457673 | 0.87 | F2 (0.42) | ITKAURKAMAP4K4CHEK2PRKCG | |
| Hydrochloric Acid SCHEMBL6159121 | 0.82 | F2 (0.60) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL6486632 | 0.79 | F2 (0.50) | ITKHDAC1HDAC8HDAC6F2 | |
| SCHEMBL7249869 | 0.78 | F2 (0.49) | ITKAURKAMAP4K4CHEK2PRKCG | |
| Hydrochloric Acid SCHEMBL7244675 | 0.78 | F2 (0.49) | ITKHDAC1HDAC8HDAC6F2 | |
| SCHEMBL7244672 | 0.78 | F2 (0.47) | ITKHDAC1HDAC8HDAC6F2 | |
| SCHEMBL7247840 | 0.78 | NSD2 (0.52) | ITKAURKAMAP4K4CHEK2PRKCG | |
| SCHEMBL6637141 | 0.77 | F2 (0.43) | ITKAURKAMAP4K4CHEK2PRKCG | |
| SCHEMBL7117035 | 0.77 | ITK (0.44) | ITKAURKAMAP4K4CHEK2PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1237877-A2 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM KG (DE) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001034572-A2 | CARBOXAMIDE-SUBSTITUTED BENZIMIDAZOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS TRYPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | CMA1, TPSD1, TPSAB1 | ITK 1616/4885AURKA 1492/4885MAP4K4 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.